Working together to protect the world

ViraCoat has partnered with the World-Class Lancaster University as the lead research facility for the rigorous testing of all ViraCorp products.

The university’s biomedical facilities and equipment are state-of-the-art, with a CL3 Laboratory and full access to the university’s resources as required for each project.

In the last REF, 91% of Lancaster’s research was rated as either internationally excellent or world leading. Lancaster University’s research is truly international in focus, with research partnerships in over 60 countries around the world.

ViraVac has partnered with Innoture, specialists in microneedle technology, to deliver the GMP for our SARS-CoV-2 transdermal patch vaccine.

Innoture’s 35 years of experience has allowed them to refine their microneedle patches and provide a range of benefits for patients, healthcare professionals, and the pharmaceutical industry in general.

The use of this technology will aid in our mission to provide vaccines to those in remote areas, where traditional vaccination methods are difficult to use.

ViraVac has partnered with Incepta Pharmaceuticals to deliver GMP for our intranasal ​​SARS-CoV-2 vaccine.

Founded in 1999, Incepta has a strong history of developing new and advanced dosage forms of various drugs to aid in the development and distribution of vaccines to more nations. They currently export to over 75 countries across the globe.

Dr Abdul Muktadir, Chairman and MD of Incepta, shares in our vision that pharmaceuticals should not be exploitative and should be made readily available at low cost for all who may need them.